Previous 10 | Next 10 |
Investors are apparently reacting to Pfizer and BioNTech's release of encouraging preliminary early-stage data on COVID-19 vaccine candidate BNT162b1 that showed significant jumps in neutralizing antibodies compared to convalescent plasma. More news on: AstraZeneca PLC, GlaxoSmithKline p...
The FDA has released guidance on its standards for approving a COVID-19 vaccine, including a requirement that it must demonstrate that it is at least 50% more effective than placebo (a low bar compared to vaccines for other infectious diseases). More news on: AstraZeneca PLC, GlaxoSmithK...
More vaccine news to catch up on - previous updates and specific topic posts on this subject were on June 15 , on June 11 , on May 26, on May 18 (with two other posts), on May 14, on May 1, on April 23, and on April 15 (author's note: yikes). Keep in mind that some of those posts were update...
OncoCyte (NYSEMKT: OCX ) -46% following unsuccessful results from a clinical validation study of DetermaDx. More news on: OncoCyte Corporation, Zynerba Pharmaceuticals, Inc., Liquidia Technologies, Inc., Stocks on the move, , Read more ...
Shares of Vaxart (NASDAQ: VXRT) were vaulting 10.8% higher as of 11:38 a.m. EDT on Monday after rising as much as 22.9% earlier in the day. The gain appears to be continued momentum from last Friday , when Vaxart's COVID-19 vaccine was selected to participate in the U.S. government's Operat...
Last week, the top-performing biotech stocks had something in common and by now you can probably guess exactly what that was. You got it. They both delivered positive press releases regarding their respective coronavirus vaccine candidates. Data source: Yahoo! Finance. Continue reading
BioHiTech Global (NASDAQ: BHTG ) +89% on potential demand for Altapure disinfectant in COVID-19. More news on: BioHiTech Global, Inc., Kiniksa Pharmaceuticals, Ltd., CleanSpark, Inc., Stocks on the move, , Read more ...
Vaxart (NASDAQ: VXRT) and VBI Vaccines (NASDAQ: VBIV) are both young vaccine companies seeking to develop a vaccine for COVID-19. Neither company is profitable, but both stocks have experienced triple-digit growth in the last three months. Future stock growth stemming from advances in v...
Vaccine startup Vaxart (NASDAQ: VXRT) announced Thursday morning that it was initiating a memorandum of understanding with Attwill Medical Solutions Sterilflow. The latter company will produce components for Vaxart's COVID-19 vaccine candidate currently in preclinical development, and Vaxart...
Shares of Vaxart (NASDAQ: VXRT) soared on Friday after the biotech company said that its oral COVID-19 vaccine had been selected to receive funding from a federal government program aiming to deliver hundreds of millions of safe and effective coronavirus vaccine doses to Americans by Janua...
News, Short Squeeze, Breakout and More Instantly...
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and noroviru...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per ...